When tested in BCL‐XL dependent ALL cells (MOLT‐4 cells) PROTAC XZ424 demonstrated to degrade the target in a time‐ and dose‐dependent manner, with a DC50 value of 50 nM. This evidence concerns the gene BCL2L1 and acute lymphoblastic leukemia.